Hypercholesterolemia - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 60
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: H5D845B9EABEN
Leaflet:

Download PDF Leaflet

Hypercholesterolemia - Pipeline Review, Q4 2010
Hypercholesterolemia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Hypercholesterolemia Pipeline Review, Q4 2010”, provides an overview of the Hypercholesterolemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. “Hypercholesterolemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Hypercholesterolemia.
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypercholesterolemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • A snapshot of the global therapeutic scenario for Hypercholesterolemia.
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypercholesterolemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercholesterolemia
Hypercholesterolemia Therapeutics under Development by Companies
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Hypercholesterolemia Therapeutics Development
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Isis Pharmaceuticals, Inc.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Recordati S.p.A.
Karo Bio
Regeneron Pharmaceuticals, Inc.
SCOLR Pharma, Inc.
Samaritan Pharmaceuticals, Inc.
Obecure Ltd.
VIA Pharmaceuticals, Inc.
Relypsa, Inc.
Universities/Institutes Involved in Hypercholesterolemia Therapeutics Development
Hypercholesterolemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Crestor + Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ezetimibe + Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0653C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pitavastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-475 + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-475 + Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Valsartan + Pravastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valsartan + Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valsartan + Simvastatin + Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Hypercholesterolemia - Featured News
Aug 11, 2010: Karo Bio To Present Clinical Phase III Development Plan For Eprotirome For Treatment Of Heterozygous Familial Hypercholesterolemia
Aug 04, 2010: Genzyme And Isis Report Results Of Two Phase III Trials Of Mipomersen
Mar 14, 2010: ACC: Rosuvastatin and Ezetimibe Combo Tops LDL Trial
Nov 17, 2009: Higher Dose Of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths And Hospitalizations Due To Heart Failure In Investigational Study
Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor
Oct 07, 2009: Welchol (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
Sep 21, 2009: Recordati Reports Phase III Data Demonstrated Pitavastatin Is Non-Inferior To Atorvastatin And Simvastatin
Sep 21, 2009: Recordati Reports Pitavastatin Demonstrates No Significant Drug-To-Drug Interaction When Administered With CYP3A4 Inhibitors
Apr 15, 2008: Welchol Added to the American College of Endocrinology/American Association of Clinical Endocrinologists “Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus”
Jan 18, 2008: Welchol(colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes First and only medication approved to reduce both A1C and LDL cholesterol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 60

LIST OF TABLES

Number of Products Under Development for Hypercholesterolemia, 2010
Products under Development for Hypercholesterolemia – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
Amgen Inc., 2010
AstraZeneca PLC, 2010
GlaxoSmithKline plc, 2010
Isis Pharmaceuticals, Inc., 2010
Merck & Co., Inc., 2010
Takeda Pharmaceutical Company Limited, 2010
Recordati S.p.A., 2010
Karo Bio, 2010
Regeneron Pharmaceuticals, Inc., 2010
SCOLR Pharma, Inc., 2010
Samaritan Pharmaceuticals, Inc., 2010
Obecure Ltd., 2010
VIA Pharmaceuticals, Inc., 2010
Relypsa, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 49

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, 2010
Products under Development for Hypercholesterolemia – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Discovery and Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 33

Ask Your Question

Hypercholesterolemia - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: